Global Anti-Neoplastic Pharmaceutical Agents Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Anti-Neoplastic Pharmaceutical Agents market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Anti-Neoplastic Pharmaceutical Agents market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Lung Cancer accounting for % of the Anti-Neoplastic Pharmaceutical Agents global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Hormones and Antagonists segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Anti-Neoplastic Pharmaceutical Agents include GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, and Becton, Dickinson and Company, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Anti-Neoplastic Pharmaceutical Agents market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Hormones and Antagonists
Microorganism Products
Plant Products
Antitumor Antibiotics
Alkylating Agents
Antimetabolites
Natural Products
Market segment by Application, can be divided into
Lung Cancer
Bladder Cancer
Breast Cancer
Cervical Cancer
Leukemia
Gynecological Cancer
Other
Market segment by players, this report covers
GlaxoSmithKline plc.
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Bristol-Myers Squibb Company
Becton, Dickinson and Company
Pfizer Inc.
Novartis AG
AstraZeneca
Gilead
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Anti-Neoplastic Pharmaceutical Agents product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Anti-Neoplastic Pharmaceutical Agents, with revenue, gross margin and global market share of Anti-Neoplastic Pharmaceutical Agents from 2019 to 2022.
Chapter 3, the Anti-Neoplastic Pharmaceutical Agents competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Anti-Neoplastic Pharmaceutical Agents market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Anti-Neoplastic Pharmaceutical Agents research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Anti-Neoplastic Pharmaceutical Agents
1.2 Classification of Anti-Neoplastic Pharmaceutical Agents by Type
1.2.1 Overview: Global Anti-Neoplastic Pharmaceutical Agents Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Type in 2021
1.2.3 Hormones and Antagonists
1.2.4 Microorganism Products
1.2.5 Plant Products
1.2.6 Antitumor Antibiotics
1.2.7 Alkylating Agents
1.2.8 Antimetabolites
1.2.9 Natural Products
1.3 Global Anti-Neoplastic Pharmaceutical Agents Market by Application
1.3.1 Overview: Global Anti-Neoplastic Pharmaceutical Agents Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Lung Cancer
1.3.3 Bladder Cancer
1.3.4 Breast Cancer
1.3.5 Cervical Cancer
1.3.6 Leukemia
1.3.7 Gynecological Cancer
1.3.8 Other
1.4 Global Anti-Neoplastic Pharmaceutical Agents Market Size & Forecast
1.5 Global Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast by Region
1.5.1 Global Anti-Neoplastic Pharmaceutical Agents Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Anti-Neoplastic Pharmaceutical Agents Market Size by Region, (2017-2022)
1.5.3 North America Anti-Neoplastic Pharmaceutical Agents Market Size and Prospect (2017-2028)
1.5.4 Europe Anti-Neoplastic Pharmaceutical Agents Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Market Size and Prospect (2017-2028)
1.5.6 South America Anti-Neoplastic Pharmaceutical Agents Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Anti-Neoplastic Pharmaceutical Agents Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Anti-Neoplastic Pharmaceutical Agents Market Drivers
1.6.2 Anti-Neoplastic Pharmaceutical Agents Market Restraints
1.6.3 Anti-Neoplastic Pharmaceutical Agents Trends Analysis
2 Company Profiles
2.1 GlaxoSmithKline plc.
2.1.1 GlaxoSmithKline plc. Details
2.1.2 GlaxoSmithKline plc. Major Business
2.1.3 GlaxoSmithKline plc. Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.1.4 GlaxoSmithKline plc. Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 GlaxoSmithKline plc. Recent Developments and Future Plans
2.2 F. Hoffmann-La Roche Ltd
2.2.1 F. Hoffmann-La Roche Ltd Details
2.2.2 F. Hoffmann-La Roche Ltd Major Business
2.2.3 F. Hoffmann-La Roche Ltd Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.2.4 F. Hoffmann-La Roche Ltd Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.3 Eli Lilly and Company
2.3.1 Eli Lilly and Company Details
2.3.2 Eli Lilly and Company Major Business
2.3.3 Eli Lilly and Company Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.3.4 Eli Lilly and Company Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Eli Lilly and Company Recent Developments and Future Plans
2.4 Bristol-Myers Squibb Company
2.4.1 Bristol-Myers Squibb Company Details
2.4.2 Bristol-Myers Squibb Company Major Business
2.4.3 Bristol-Myers Squibb Company Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.4.4 Bristol-Myers Squibb Company Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.5 Becton, Dickinson and Company
2.5.1 Becton, Dickinson and Company Details
2.5.2 Becton, Dickinson and Company Major Business
2.5.3 Becton, Dickinson and Company Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.5.4 Becton, Dickinson and Company Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Becton, Dickinson and Company Recent Developments and Future Plans
2.6 Pfizer Inc.
2.6.1 Pfizer Inc. Details
2.6.2 Pfizer Inc. Major Business
2.6.3 Pfizer Inc. Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.6.4 Pfizer Inc. Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Pfizer Inc. Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.7.4 Novartis AG Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.8.4 AstraZeneca Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 AstraZeneca Recent Developments and Future Plans
2.9 Gilead
2.9.1 Gilead Details
2.9.2 Gilead Major Business
2.9.3 Gilead Anti-Neoplastic Pharmaceutical Agents Product and Solutions
2.9.4 Gilead Anti-Neoplastic Pharmaceutical Agents Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Gilead Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Anti-Neoplastic Pharmaceutical Agents Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Anti-Neoplastic Pharmaceutical Agents Players Market Share in 2021
3.2.2 Top 10 Anti-Neoplastic Pharmaceutical Agents Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Anti-Neoplastic Pharmaceutical Agents Players Head Office, Products and Services Provided
3.4 Anti-Neoplastic Pharmaceutical Agents Mergers & Acquisitions
3.5 Anti-Neoplastic Pharmaceutical Agents New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Anti-Neoplastic Pharmaceutical Agents Revenue and Market Share by Type (2017-2022)
4.2 Global Anti-Neoplastic Pharmaceutical Agents Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Application (2017-2022)
5.2 Global Anti-Neoplastic Pharmaceutical Agents Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2028)
6.2 North America Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2028)
6.3 North America Anti-Neoplastic Pharmaceutical Agents Market Size by Country
6.3.1 North America Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2028)
6.3.2 United States Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
6.3.3 Canada Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
6.3.4 Mexico Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2028)
7.2 Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2028)
7.3 Europe Anti-Neoplastic Pharmaceutical Agents Market Size by Country
7.3.1 Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2028)
7.3.2 Germany Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
7.3.3 France Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
7.3.5 Russia Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
7.3.6 Italy Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2028)
8.2 Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2028)
8.3 Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Market Size by Region
8.3.1 Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Region (2017-2028)
8.3.2 China Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
8.3.3 Japan Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
8.3.4 South Korea Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
8.3.5 India Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
8.3.7 Australia Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2028)
9.2 South America Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2028)
9.3 South America Anti-Neoplastic Pharmaceutical Agents Market Size by Country
9.3.1 South America Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2028)
9.3.2 Brazil Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
9.3.3 Argentina Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2028)
10.2 Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2028)
10.3 Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Market Size by Country
10.3.1 Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2028)
10.3.2 Turkey Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
10.3.4 UAE Anti-Neoplastic Pharmaceutical Agents Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Anti-Neoplastic Pharmaceutical Agents Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Anti-Neoplastic Pharmaceutical Agents Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Anti-Neoplastic Pharmaceutical Agents Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) by Region (2017-2022)
Table 5. Global Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Region (2023-2028)
Table 6. GlaxoSmithKline plc. Corporate Information, Head Office, and Major Competitors
Table 7. GlaxoSmithKline plc. Major Business
Table 8. GlaxoSmithKline plc. Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 9. GlaxoSmithKline plc. Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 11. F. Hoffmann-La Roche Ltd Major Business
Table 12. F. Hoffmann-La Roche Ltd Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 13. F. Hoffmann-La Roche Ltd Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 15. Eli Lilly and Company Major Business
Table 16. Eli Lilly and Company Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 17. Eli Lilly and Company Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 19. Bristol-Myers Squibb Company Major Business
Table 20. Bristol-Myers Squibb Company Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 21. Bristol-Myers Squibb Company Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Becton, Dickinson and Company Corporate Information, Head Office, and Major Competitors
Table 23. Becton, Dickinson and Company Major Business
Table 24. Becton, Dickinson and Company Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 25. Becton, Dickinson and Company Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Pfizer Inc. Major Business
Table 28. Pfizer Inc. Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 29. Pfizer Inc. Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 31. Novartis AG Major Business
Table 32. Novartis AG Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 33. Novartis AG Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 35. AstraZeneca Major Business
Table 36. AstraZeneca Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 37. AstraZeneca Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Gilead Corporate Information, Head Office, and Major Competitors
Table 39. Gilead Major Business
Table 40. Gilead Anti-Neoplastic Pharmaceutical Agents Product and Solutions
Table 41. Gilead Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Anti-Neoplastic Pharmaceutical Agents Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Anti-Neoplastic Pharmaceutical Agents by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Anti-Neoplastic Pharmaceutical Agents Players Head Office, Products and Services Provided
Table 46. Anti-Neoplastic Pharmaceutical Agents Mergers & Acquisitions in the Past Five Years
Table 47. Anti-Neoplastic Pharmaceutical Agents New Entrants and Expansion Plans
Table 48. Global Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) by Type (2017-2022)
Table 49. Global Anti-Neoplastic Pharmaceutical Agents Revenue Share by Type (2017-2022)
Table 50. Global Anti-Neoplastic Pharmaceutical Agents Revenue Forecast by Type (2023-2028)
Table 51. Global Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2022)
Table 52. Global Anti-Neoplastic Pharmaceutical Agents Revenue Forecast by Application (2023-2028)
Table 53. North America Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Anti-Neoplastic Pharmaceutical Agents Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Anti-Neoplastic Pharmaceutical Agents Picture
Figure 2. Global Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Type in 2021
Figure 3. Hormones and Antagonists
Figure 4. Microorganism Products
Figure 5. Plant Products
Figure 6. Antitumor Antibiotics
Figure 7. Alkylating Agents
Figure 8. Antimetabolites
Figure 9. Natural Products
Figure 10. Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Application in 2021
Figure 11. Lung Cancer Picture
Figure 12. Bladder Cancer Picture
Figure 13. Breast Cancer Picture
Figure 14. Cervical Cancer Picture
Figure 15. Leukemia Picture
Figure 16. Gynecological Cancer Picture
Figure 17. Other Picture
Figure 18. Global Anti-Neoplastic Pharmaceutical Agents Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 19. Global Anti-Neoplastic Pharmaceutical Agents Revenue and Forecast (2017-2028) & (USD Million)
Figure 20. Global Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Region (2017-2028)
Figure 21. Global Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Region in 2021
Figure 22. North America Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Europe Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) and Growth Rate (2017-2028)
Figure 24. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) and Growth Rate (2017-2028)
Figure 25. South America Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) and Growth Rate (2017-2028)
Figure 26. Middle East and Africa Anti-Neoplastic Pharmaceutical Agents Revenue (USD Million) and Growth Rate (2017-2028)
Figure 27. Anti-Neoplastic Pharmaceutical Agents Market Drivers
Figure 28. Anti-Neoplastic Pharmaceutical Agents Market Restraints
Figure 29. Anti-Neoplastic Pharmaceutical Agents Market Trends
Figure 30. GlaxoSmithKline plc. Recent Developments and Future Plans
Figure 31. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 32. Eli Lilly and Company Recent Developments and Future Plans
Figure 33. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 34. Becton, Dickinson and Company Recent Developments and Future Plans
Figure 35. Pfizer Inc. Recent Developments and Future Plans
Figure 36. Novartis AG Recent Developments and Future Plans
Figure 37. AstraZeneca Recent Developments and Future Plans
Figure 38. Gilead Recent Developments and Future Plans
Figure 39. Global Anti-Neoplastic Pharmaceutical Agents Revenue Share by Players in 2021
Figure 40. Anti-Neoplastic Pharmaceutical Agents Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 41. Global Top 3 Players Anti-Neoplastic Pharmaceutical Agents Revenue Market Share in 2021
Figure 42. Global Top 10 Players Anti-Neoplastic Pharmaceutical Agents Revenue Market Share in 2021
Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 44. Global Anti-Neoplastic Pharmaceutical Agents Revenue Share by Type in 2021
Figure 45. Global Anti-Neoplastic Pharmaceutical Agents Market Share Forecast by Type (2023-2028)
Figure 46. Global Anti-Neoplastic Pharmaceutical Agents Revenue Share by Application in 2021
Figure 47. Global Anti-Neoplastic Pharmaceutical Agents Market Share Forecast by Application (2023-2028)
Figure 48. North America Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Type (2017-2028)
Figure 49. North America Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Application (2017-2028)
Figure 50. North America Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Country (2017-2028)
Figure 51. United States Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Canada Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Mexico Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Europe Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Type (2017-2028)
Figure 55. Europe Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Application (2017-2028)
Figure 56. Europe Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Country (2017-2028)
Figure 57. Germany Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. France Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. United Kingdom Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Russia Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Italy Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Type (2017-2028)
Figure 63. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Application (2017-2028)
Figure 64. Asia-Pacific Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Region (2017-2028)
Figure 65. China Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Japan Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South Korea Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. India Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Southeast Asia Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Australia Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. South America Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Type (2017-2028)
Figure 72. South America Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Application (2017-2028)
Figure 73. South America Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Country (2017-2028)
Figure 74. Brazil Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Argentina Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Middle East and Africa Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Anti-Neoplastic Pharmaceutical Agents Sales Market Share by Application (2017-2028)
Figure 78. Middle East and Africa Anti-Neoplastic Pharmaceutical Agents Revenue Market Share by Country (2017-2028)
Figure 79. Turkey Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Saudi Arabia Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. UAE Anti-Neoplastic Pharmaceutical Agents Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Methodology
Figure 83. Research Process and Data Source
